Sirnaomics' siRNA Therapeutic Candidate, STP705, Granted Orphan Drug Designation By US FDA for Treatment of Hepatocellular Carcinoma

GAITHERSBURG, Md., Feb. 10, 2020 /PRNewswire/ -- Sirnaomics, Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Office of Orphan Product Development division of the FDA has granted orphan drug designation to its leading...

from PR Newswire: https://ift.tt/2HdPCAQ